Stay Connected

Tag: Novo Nordisk

Post navigation

Data from the A1chieve® study, evaluating adverse events and effectiveness of Novo Nordisk insulins (NovoMix 30, Levemir and NovoRapid) in 66,726 people with type 2 diabetes, shows that type 2 diabetes patients can significantly improve their blood glucose control with a low occurrence of low blood sugar (hypoglycemia)… Read more

Novo Nordisk and Chip Ganassi Racing Teams announced that the two organizations have entered into a multi-year extension of their partnership sponsoring No. 83 Novo Nordisk Chip Ganassi Racing entry, driven by Charlie Kimball in the IZOD IndyCar Series. Charlie Kimball is the first licensed driver with type 1 diabetes… Read more

Victoza, Novo Nordisks best selling type 2 diabetes drug is now commercially available in China. Victoza, (liraglutide injection), the first once-daily human Glucagon-Like Peptide-1 (GLP-1) analog, was approved for type 2 diabetes by the Chinese State Food and Drug Administration in March 2011… Read more

Novo Nordisk filed two new drug applications for the approval of ultra-long-acting insulin degludec and the co-formulation, insulin degludec/insulin aspart (DegludecPlus) by the U.S. Food and Drug Administration. These new insulin analogs have been developed for the treatment of people with type 1 and type 2 diabetes. Read more

Following a review of new data from a 52-week clinical trial, the European Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion on the usage of Novo Nordisk’s basal insulin analogue, Levemir, as add-on therapy to Novo Nordisk’s GLP-1 analogue, Victoza, in combination with metformin in patients with type 2 diabetes… Read more

The European Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion on the extended use of Novo Nordisk’s basal insulin analogue, insulin detemir, in children with type 1 diabetes, aged two to five years. The CHMP decision was made after the review of data demonstrating that insulin detemir… Read more

Novo Nordisk’s ultra-long-acting insulin degludec, an investigational basal insulin being developed, showed significant blood sugar reductions in patients with type 2 diabetes even when doses were given once-daily up to 40 hours apart, according to data presented today at the European Association for the Study of Diabetes (EASD) in Lisbon… Read more

New data presented at the European Association for the Study of Diabetes (EASD) shows a significantly higher proportion of patients reached target HbA1c levels of <7% when Victoza (liraglutide [rDNA origin] injection) was administrated early in the treatment of type 2 diabetes to patients who had not received treatment before or had previously received only one oral anti-diabetic drug (OAD)... Read more